- Our World
- Our Business
- Life at Lupin
- Global Sites
Mumbai, Baltimore, March 02, 2017: Pharma Major Lupin Limited (Lupin) announced today the launch of generic Pristiq® (Desvenlafaxine Succinate) Extended-Release Tablets, 50 mg and 100 mg having received an approval from the United States Food and Drug Administration (FDA) earlier.
Lupin’s Desvenlafaxine Succinate Extended-Release Tablets, 50 mg and 100 mg is the AB rated generic equivalent of Wyeth Pharmaceuticals’ Pristiq® Tablets. It is indicated for the treatment of major depressive disorder (MDD).
Pristiq® Tablets had annual US sales of approximately USD 859.9 million (IMS MAT December 2016).
About Lupin Limited
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.
Lupin is the 5th and the 6th largest generics pharmaceutical company by market capitalization (December 31st, 2016, Bloomberg) and sales globally (September 30th, 2016, Bloomberg). The Company is the 5th largest pharmaceutical player in the US by prescriptions (4.68% market share – IMS Health, National Prescription Audit, March 2016); the 2nd largest Indian pharmaceutical company by revenues; the 6th largest generic pharmaceutical player in Japan and the 4th largest generic pharmaceutical company in South Africa (IMS Health, March 2016).
For the financial year ended 31st March, 2016, Lupin’s Consolidated sales and Net profit stood at Rs. 136,539 million (USD 2.09 billion) and Rs. 22,607 million (USD 345 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter – www.twitter.com/lupinlimited
CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.
For further information or queries please contact –
Head – Investor Relations and M&A
Ph: +91-70 45 656 895
Pristiq® is the registered trademark of Wyeth LLC.